Elutia announces new peer reviewed publication on EluPro

Elutia announced the publication of preclinical data demonstrating that EluPro, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration, FDA, clears bacterial contamination associated with cardiovascular implantable electronic devices, CIEDs. Data published in Frontiers in Drug Delivery show that in an animal model, EluPro demonstrated the ability to reduce bacterial colonization with minimal systemic antibiotic exposure. “We believe these results greatly reinforce EluPro’s potential to provide enhanced infection control for CIED procedures,” said Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer. “As the first FDA-cleared biologic antibiotic-eluting envelope, EluPro represents a significant step forward in implantable device protection. With our recent milestone of the first human implant, we are preparing for the commercial launch of EluPro in January 2025.”